Amgen Articles
Amgen buys BioVex for up to $1 billion; posts better-than-expected 4th-qrt 2010 results, with GAAP EPS growth at 11%
25 January 2011
AstraZeneca unit MedImmune in-licenses anti-inflammatory MAb from Amgen; latter’s Sensipar patent upheld
10 January 2011
Amgen and Xencor ink $500 million option pact to co-develop novel antibody for autoimmune diseases
7 January 2011
Intercell’s Travelers’ diarrhea vaccine and Lilly’s tasisulam flop; Amgen’s Xgeva looks good
14 December 2010
US FDA approves expanded use of Amgen’s bone drug denosumab, which could boost potential sales to $2.4 billion
19 November 2010
New guideline from ASH and ASCO recommends caution regarding ESA use in cancer patients
28 October 2010
Negative decisions from UK’s NICE for Novartis’ Xolair, GSK’s Arzerra and Pfizer’s Torisel, but OK for Amgen’s Prolia
27 October 2010
US FDA advisory panel backs continued use of Amgen’s Aranesp and Epogen pre-dialysis, but calls for more studies
19 October 2010
US FDA to review use of anemia drugs from Amgen and Johnson & Johnson; Commissioner calls for shift in traditional testing methods
15 October 2010
Experts and patient groups highlight urgent need for improvement in the management of osteoporosis in the UK
13 October 2010
Strong cancer drug results presented by Roche, Sanofi-Aventis, Merck KGaA, Amgen and Eisai at ESMO Congress
12 October 2010
Robust uptake of Amgen/GlaxoSmithKline's Prolia for the treatment of osteoporosis projected
1 October 2010
Sanofi facing generic Taxotere competition in USA; first biosimilar cleared in Australia
30 September 2010
Top-line results of Ph III head and neck cancer trial with Amgen’s Vectibix disappoint
12 August 2010
Following US and European approval, Amgen/GSK’s Prolia will garner sales of more than $500 million in 2019
7 July 2010
Two different stories as US biotechs Amgen and Genzyme post first-quarter 2010 results
22 April 2010
Japan’s Takeda gets five new products approved on home market, and partner Amgen reveals strong results with Vectibix
19 April 2010
Drug's effect on reduction of new hip fractures is greatest influence on Rxing decisions, says DR report
5 March 2010
FDA agrees plan requiring Amgen and J&J unit to educate doctors and patients on risks of anemia drugs
17 February 2010
Vernalis to re-acquire EU frovatriptan royalties; Isogenica gains rights to commercialize drugs with MRSA potential
15 February 2010
Increasing competition from other biologics will continue to erode Enbrel's dominance in the psoriasis drug market, DR report concludes
12 February 2010
Analysts see positive future for Amgen’s bone metastases drug denosumab following strong Ph III data
10 February 2010
Amgen's fourth quarter 2009 earnings slightly below consensus analyst’s expectations
26 January 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
Genzyme manufacturing woes hit sales; Amgen forecasts lower-end of expectations EPS and signs deal with MedGenisis
13 January 2010
FDA finally approves Roche’s Actemra for moderately-to-severely active rheumatoid arthritis
11 January 2010
Court blocks Roche’s sales of Mircera in USA until 2014, as Amgen prevails in EPO patent dispute
23 December 2009
Europe’s CHMP serves up negative opinion for Ark’s Cerepro and calls for ban on benfluorex drugs, but good news for B-MS, Sanofi, GSK, Novartis
21 December 2009
Takeda gets rights to Seattle’s brentuximab and picks Pfizer for Actos in China; and Amgen licenses diabetes drug
15 December 2009
Teva files BLA for XM02 with FDA for chemotherapy-induced neutropenia; a challenge to Amgen’s Neupogen?
2 December 2009
Cancer pain drug market, fueled by opioids, will increase from $2.3 billion in 2008 to $3.7 billion in 2018
25 November 2009
Merck KGaA gets second CHMP rejection for Erbitux in Advanced Non-Small Cell Lung Cancer
20 November 2009
ImmunoGen enters second licensing deal with Amgen, worth up to $34 million; presents strong data on IMGN901
20 November 2009
Biotech takes it on the chin in October
5 November 2009
Biosimilars of TNF-alpha inhibitors stand to erode over $9 billion in brand sales in USA and Europe by 2018
4 November 2009
Amgen’s Aranesp did not meet endpoints and increased risk of stroke; firm accused of kickbacks
2 November 2009
Cost-cutting helps Amgen lift 3rd quarter 2009 EPS 21%
22 October 2009
Amgen’s Prolia BLS delayed by FDA call for more info
20 October 2009
UCB’s Cimzia approved for RA in Europe
7 October 2009
Amgen’s pipeline boosted by new denosumab data
23 September 2009
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will erode $8.2 billion in US and European sales in 2018
17 September 2009
US Appeals Court backs Amgen against Roche’s peg-EPO product
16 September 2009
Amgen’s denosumab gets mixed backing from US FDA panel
14 August 2009
Amgen scores with cancer drug, says Zacks analysts
10 August 2009
US FDA says cancer warnings required for TNF blockers
5 August 2009
Amgen's Nplate reduces number of splenectomies
8 June 2009
Amgen pays $50M to option Cytokinetics drug
28 May 2009
Amgen pays $50M to option Cytokinetics' HF drug
26 May 2009
Japan stock market week to May 4, 2009
5 May 2009
Stock Commentary - New York week to April 27, 2009
30 April 2009
Wyeth's first-quarter 2009 profit flat year-on-year as it prepares for Pfizer mega-merger
29 April 2009
Falling profit on low sales for Amgen
27 April 2009
NexGen founder's patent improves chemo
30 March 2009
Stock Commentary - New York week to Mar 9, 2009
16 March 2009
Amgen set to decide on Cytokinetics license
9 March 2009
FDA accepts Amgen's denosumab BLA
23 February 2009
Amgen/Takeda resume motesanib development
23 February 2009
Amgen gets EC appro for Nplate in ITC
16 February 2009
Sanofi has $5.1B and is looking for M&A deals
9 February 2009
Leptin sensitizers lead to weight loss in mice
26 January 2009
Japan stock market week to Jan 19, 2009
26 January 2009
GSK to stop making political donations
12 January 2009
Stock Commentary - New York week to Jan 5, 2009
12 January 2009
FDA 2008 NCE appros exceed expectations
12 January 2009
CEO says Pfizer is open to "mega-merger"
12 January 2009
Amgen submits BLA for denosumab to US FDA
12 January 2009
FDA may insist on KRAS tests for cancer patients
22 December 2008
ASH hears strong data on Novartis
22 December 2008
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
